Normal view MARC view ISBD view

Fibrinolytic Bacterial Enzymes with Thrombolytic Activity [electronic resource] / by Essam Kotb.

By: Kotb, Essam [author.].
Contributor(s): SpringerLink (Online service).
Material type: materialTypeLabelBookSeries: SpringerBriefs in Microbiology: Publisher: Berlin, Heidelberg : Springer Berlin Heidelberg, 2012Description: XII, 74p. 15 illus., 6 illus. in color. online resource.Content type: text Media type: computer Carrier type: online resourceISBN: 9783642249808.Subject(s): Medicine | Human physiology | Microbiology | Cardiology | Hematology | Biomedicine | Medical Microbiology | Hematology | Cardiology | Human PhysiologyDDC classification: 616.9041 Online resources: Click here to access online In: Springer eBooksSummary: Stress, high blood pressure, smoking, pollution, fast foods, overweight, excessive travelling, surgery, less movement are common features in our modern life. These features are risky for blood clotting disorders. According to WHO, over 29% of the total mortalities worldwide are due to thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause an estimated 25 million deaths per year, thus antithrombotic therapy is of great interest. The available thrombolytic agents such as urokinase are highly expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic. Therefore, the production of fibrinolysing enzymes, which rapidly dissolute thrombi within the vascular tree, without the detriments by microorganisms, as described in this book, is the desirable aim of today’s research.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Stress, high blood pressure, smoking, pollution, fast foods, overweight, excessive travelling, surgery, less movement are common features in our modern life. These features are risky for blood clotting disorders. According to WHO, over 29% of the total mortalities worldwide are due to thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause an estimated 25 million deaths per year, thus antithrombotic therapy is of great interest. The available thrombolytic agents such as urokinase are highly expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic. Therefore, the production of fibrinolysing enzymes, which rapidly dissolute thrombi within the vascular tree, without the detriments by microorganisms, as described in this book, is the desirable aim of today’s research.

There are no comments for this item.

Log in to your account to post a comment.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue